Search Results

You are looking at 71 - 80 of 91 items for :

  • "cytoreduction" x
  • Refine by Access: All x
Clear All
Full access

Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer

Andrew H. Ko and Christopher H. Crane

-based chemotherapy followed by radiation (50.4 Gy in 28 fractions) with concurrent gemcitabine. General agreement exists that radiation plays an important role in this subset of patients, in whom initial cytoreduction to achieve an R0 resection is the ultimate goal

Full access

Controversies in the Locoregional Management of Head and Neck Cancer

David M. Brizel, William Lydiatt, and A. Dimitrios Colevas

. The use of cisplatin dates back to the early 1970s when it became apparent that cisplatin as a single agent and combined with other agents caused significant cytoreduction in SCCHN. The initial report of chemotherapy involving cisplatin plus bleomycin

Full access

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania

. Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1,000 surgical cytoreductions by a single institution . J Am Coll Surg 2017 ; 224 : 434 – 447 . 59. Mayo SC de Jong MC Pulitano C . Surgical management of hepatic

Full access

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024

Featured Updates to the NCCN Guidelines

Jason Gotlib, Aaron T. Gerds, Peter Abdelmessieh, Haris Ali, Mariana Castells, Andrew Dunbar, Ruth Fein Revell, Tracy I. George, Steven Green, Krishna Gundabolu, Elizabeth Hexner, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Naveen Manchanda, Lucia Masarova, Jori May, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Jeanne Palmer, Ami Patel, Anand A. Patel, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Moshe Talpaz, Martha Wadleigh, Sarah Wall, Mary Anne Bergman, and Cindy Hochstetler

cytostatic mechanism of action, responses may take longer to emerge, and the use of interferons may be more suitable for patients with slowly progressive disease without the need for rapid cytoreduction. In the current era of KIT inhibitors, the therapeutic

Full access

Acute Myeloid Leukemia

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

differentiating action of ATRA occurs over a longer period than the cytoreduction of conventional chemotherapy, early marrow evaluations for hematologic response at day 7 to 14 after induction are misleading and may lead to overtreatment. Marrow evaluation is not

Full access

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba

/APL, antecedent MDS/CMML, or AML-MRC. 40 Treatments for induction failure may also be considered. For patients with significant (>50%) cytoreduction and a low percentage of residual blasts (as defined previously; see AML-9, page 724), standard-dose cytarabine

Full access

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Prithviraj Bose and Srdan Verstovsek

therapy in these conditions has mostly been limited to the use of aspirin 29 and hydroxyurea or anagrelide (in ET) in high-risk patients requiring cytoreduction for prevention of thrombotic complications. 30 – 32 Hematocrit control (to <45%) 33 in low

Full access

Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, and Ruben A. Mesa

with cytoreduction, 17 developed leukemia. Of these, 14 were treated with hydroxyurea; a high proportion had 17p deletions. 53 Associations with genetic alterations of 17p (including p53), hydroxyurea exposure, and evolution to MPN blast phase have

Full access

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M. Boughan, Bouthaina Dabaja, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Alex F. Herrera, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Matthew McKinney, Monika Metzger, David Morgan, Carolyn Mulroney, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

these prognostic factor studies is to facilitate comparison of outcomes at different centers, where the preparatory regimens may vary. Several studies have shown the importance of cytoreduction with second-line chemotherapy before HDT/ASCR. 114 , 125

Full access

Hodgkin Lymphoma

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter, and Joachim Yahalom

main potential of these prognostic factor studies is to facilitate comparison of outcomes at different centers, where the preparatory regimens may vary. Second-Line Chemotherapy Several studies have shown the importance of cytoreduction with